Income Statement West Pharmaceutical Services, Inc.
Stocks
WST
US9553061055
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 359.70 USD | +1.69% |
|
+0.58% | +30.73% |
| 13/07 | BNP Paribas Initiates West Pharmaceutical Services at Outperform With $447 Price Target | MT |
| 13/07 | BNP Paribas Initiates West Pharmaceutical Services at Outperform With $447 Price Target | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 283.16Cr | 288.69Cr | 294.98Cr | 289.32Cr | 307.41Cr | |||||
Total Revenues | 283.16Cr | 288.69Cr | 294.98Cr | 289.32Cr | 307.41Cr | |||||
Cost of Goods Sold, Total | 165.58Cr | 175.07Cr | 181.98Cr | 189.47Cr | 197.01Cr | |||||
Gross Profit | 117.58Cr | 113.62Cr | 113Cr | 100Cr | 110.4Cr | |||||
Selling General & Admin Expenses, Total | 36Cr | 32Cr | 35Cr | 33Cr | 39Cr | |||||
R&D Expenses | 5.28Cr | 5.85Cr | 6.84Cr | 6.91Cr | 7.43Cr | |||||
Other Operating Expenses | - | -21L | 13L | 9L | 13L | |||||
Other Operating Expenses, Total | 41Cr | 37Cr | 42Cr | 40Cr | 47Cr | |||||
Operating Income | 76Cr | 76Cr | 71Cr | 59Cr | 64Cr | |||||
Interest Expense, Total | -82L | -79L | -90L | -30L | -5L | |||||
Interest And Investment Income | 10L | 51L | 2.8Cr | 1.96Cr | 1.75Cr | |||||
Net Interest Expenses | -72L | -28L | 1.9Cr | 1.66Cr | 1.7Cr | |||||
Income (Loss) On Equity Invest. | 2.01Cr | 2.07Cr | 1.77Cr | 1.47Cr | 1.44Cr | |||||
Currency Exchange Gains (Loss) | 14L | 41L | -94L | -1.02Cr | -84L | |||||
EBT, Excl. Unusual Items | 78Cr | 79Cr | 73Cr | 61Cr | 66Cr | |||||
Restructuring Charges | -22L | -2.38Cr | 20L | -21L | -2.95Cr | |||||
Gain (Loss) On Sale Of Investments | -43L | -35L | -43L | -3L | -45L | |||||
Gain (Loss) On Sale Of Assets | - | - | -1.16Cr | - | - | |||||
Asset Writedown | -13L | -27L | -53L | -70L | -37L | |||||
Legal Settlements | - | - | 38L | - | - | |||||
Other Unusual Items | -15L | -5.52Cr | -24L | -51L | -87L | |||||
EBT, Incl. Unusual Items | 77Cr | 70Cr | 72Cr | 60Cr | 62Cr | |||||
Income Tax Expense | 11Cr | 11Cr | 12Cr | 11Cr | 12Cr | |||||
Earnings From Continuing Operations | 66Cr | 59Cr | 59Cr | 49Cr | 49Cr | |||||
Net Income to Company | 66Cr | 59Cr | 59Cr | 49Cr | 49Cr | |||||
Net Income - (IS) | 66Cr | 59Cr | 59Cr | 49Cr | 49Cr | |||||
Net Income to Common Incl Extra Items | 66Cr | 59Cr | 59Cr | 49Cr | 49Cr | |||||
Net Income to Common Excl. Extra Items | 66Cr | 59Cr | 59Cr | 49Cr | 49Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 8.9 | 7.88 | 7.99 | 6.75 | 6.83 | |||||
Basic EPS - Continuing Operations | 8.9 | 7.88 | 7.99 | 6.75 | 6.83 | |||||
Basic Weighted Average Shares Outstanding | 7.44Cr | 7.44Cr | 7.43Cr | 7.3Cr | 7.23Cr | |||||
Net EPS - Diluted | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 | |||||
Diluted EPS - Continuing Operations | 8.67 | 7.73 | 7.88 | 6.69 | 6.79 | |||||
Diluted Weighted Average Shares Outstanding | 7.63Cr | 7.58Cr | 7.53Cr | 7.37Cr | 7.27Cr | |||||
Normalized Basic EPS | 6.54 | 6.6 | 6.17 | 5.26 | 5.72 | |||||
Normalized Diluted EPS | 6.38 | 6.48 | 6.09 | 5.21 | 5.69 | |||||
Dividend Per Share | 0.69 | 0.73 | 0.77 | 0.81 | 0.85 | |||||
Payout Ratio | 7.72 | 9.23 | 9.61 | 12 | 12.4 | |||||
Supplemental Items | ||||||||||
EBITDA | 89Cr | 88Cr | 84Cr | 75Cr | 81Cr | |||||
EBITA | 77Cr | 77Cr | 71Cr | 60Cr | 64Cr | |||||
EBIT | 76Cr | 76Cr | 71Cr | 59Cr | 64Cr | |||||
EBITDAR | 91Cr | 91Cr | 88Cr | 78Cr | 85Cr | |||||
Effective Tax Rate - (Ratio) | 13.94 | 16.37 | 17.09 | 17.91 | 19.76 | |||||
Current Domestic Taxes | 7.57Cr | 8.41Cr | 2.6Cr | 3.19Cr | 5.23Cr | |||||
Current Foreign Taxes | 7.44Cr | 6.14Cr | 5.88Cr | 7.91Cr | 8.3Cr | |||||
Total Current Taxes | 15Cr | 15Cr | 8.48Cr | 11Cr | 14Cr | |||||
Deferred Domestic Taxes | 73L | -2.03Cr | -1.16Cr | -1.83Cr | -1.4Cr | |||||
Deferred Foreign Taxes | -5.02Cr | -1.05Cr | 4.91Cr | 1.48Cr | 3L | |||||
Total Deferred Taxes | -4.29Cr | -3.08Cr | 3.75Cr | -35L | -1.37Cr | |||||
Normalized Net Income | 49Cr | 49Cr | 46Cr | 38Cr | 41Cr | |||||
Interest Capitalized | 20L | 37L | 58L | 1.32Cr | 1.46Cr | |||||
Interest on Long-Term Debt | 1.02Cr | 1.16Cr | 1.48Cr | 1.62Cr | 1.51Cr | |||||
Non-Cash Pension Expense | -20L | 5.26Cr | 22L | 24L | 21L | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 5.28Cr | 5.85Cr | 6.84Cr | 6.91Cr | 7.43Cr | |||||
Net Rental Expense, Total | 1.88Cr | 2.36Cr | 3.19Cr | 3.57Cr | 4.01Cr | |||||
Imputed Operating Lease Interest Expense | 46.73L | 68.1L | 1.2Cr | 1.51Cr | 1.53Cr | |||||
Imputed Operating Lease Depreciation | 1.41Cr | 1.68Cr | 1.99Cr | 2.06Cr | 2.48Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | 3.75Cr | 2.37Cr | 2.33Cr | 1.87Cr | 2.38Cr | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 3.75Cr | 2.37Cr | 2.33Cr | 1.87Cr | 2.38Cr |
- Stock Market
- Stocks
- WST Stock
- Financials West Pharmaceutical Services, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















